Abstract
Acute hypothyroidism induced by thyroid hormone withdrawal in patients with differentiated thyroid cancer during monitoring for remnant or metastatic disease, seriously affects multiple organs and systems, and especially in severe cases can impair quality of life. Indeed, it may induce untoward cardiovascular effects and can be hazardous in patients with underlying cardiovascular disease, particularly in the elderly. Moreover, acute hypothyroidism deranges the lipid profile and exacerbates neuropsychiatric illness. The introduction of recombinant human TSH (rhTSH) as a diagnostic and therapeutic tool in the care of patients with thyroid cancer has widened the scope of disease management. The use of rhTSH prevents derangement of various systems at approximately equivalent societal costs to that of withdrawal and promotes compliance while preserving the patient’s normal daily functioning and productivity. Its reliability allied with its safety render this compound a valid alternative in the monitoring of patients with differentiated thyroid carcinoma as well as providing an alternative therapeutic procedure whenever LT4-withdrawal may be hazardous or in cases of patient non-compliance.
Introduction
The incidence of differentiated thyroid cancer (DTC) is on the increase worldwide though the statistics may simply reflect enhanced detection of subclinical disease rather than an actual increase (1). The most widely established treatment consists of total thyroidectomy and ablation of any thyroid remnant with radioiodine (131I), followed by thyroid-stimulating hormone (TSH) suppressive treatment with levothyroxine (LT4) (2). In recent years, the development of more effective treatment and the introduction of new follow-up modalities of DTC have led to modifications in follow-up management in relation to the clinical spectrum of the disease (3–5).
The traditional follow-up of DTC, which is designed to detect persistent or recurrent disease, entails evaluation of the tumor marker thyroglobulin (Tg), neck ultrasonography and, in some cases, total body scan with 131I. A high level of TSH improves the sensitivityof Tg monitoring and is required to stimulate sufficient radioiodine uptake for diagnostic imaging or therapy (6). This can be obtained either by prolonged withdrawal of thyroid hormone treatment or by injections of recombinant human TSH (rhTSH; TSH-α; Thyrogen®) (7–10). The standard procedure is to withdraw LT4 therapy in order to stimulate endogenous TSH, thereby inducing short-term hypothyroidism. According to the consensus of European Thyroid Association and the guidelines of American Thyroid Association for patients undergoing radioiodine therapy or diagnostic testing, LT4 can be withdrawn for at least 3 weeks, or alternatively LT3 can be administered for 2 weeks followed by LT3-withdrawal for 2 weeks (11, 12). Both procedures result in serum TSH levels higher than 30 mU/l in about 90% of patients. However, although this protocol prevents long-term hypothyroidism, it restricts patient’s daily functioning, rhTSH being less restricting in this respect (10, 13).
Long-standing hypothyroidism has profound effects on multiple organs and systems: it exacerbates neuropsychiatric illness and cardiovascular disease, negatively influences lipid metabolism, and increases atherosclerotic risk, though these changes are usually reversible via achievement of euthyroidism (14–16). In contrast, there is a paucity of data on the effects of short-term hypothyroidism induced by LT4-withdrawal on metabolism, possibly due to the reversibility of these results and to the variability of LT4-withdrawal protocols.
With the increasing awareness that various degrees of long-term hypothyroidism contribute significantly to the morbidity resulting from dyslipidemia, and cardiovascular and neuropsychiatric disease, we have reviewed the data on the implications of short-term hypothyroidism after thyroidectomy in patients with DTC during LT4-withdrawal for diagnostic purposes.
Cardiovascular effects of short-term hypothyroidism
Thyroid hormone deficiency is known to seriously affect the cardiovascular system (17). Both subclinical and overt hypothyroidism have been associated with normal/depressed systolic function, left ventricular diastolic dysfunction at rest, systolic and diastolic dysfunction during effort, increased peripheral vascular resistance, and impaired endothelial function (18, 19). The similar pattern of these cardiovascular abnormalities in subclinical and overt hypothyroidism suggests that there is a continuum in cardiovascular effects related to thyroid hormone deficiencyand also that a lesser degree of thyroid hormone deficiency may induce severe cardiovascular abnormalities. Moreover, cardiovascular function was found to be impaired not only in long-standing but also in short-term hypothyroidism (20–29).
However, it should be underlined that it is difficult to evaluate data about the effects of short-term hypothyroid-ism on the cardiovascular system, because the protocols used differ among the various studies, and in some cases severe hypothyroidism was induced by LT4-withdrawal. Furthermore, many studies have evaluated the cardiovascular effects of acute hypothyroidism during LT4-withdrawal in patients with DTC as compared with controls and/or with the same patients evaluated during TSH-suppressive therapy with levothyroxine. Compared with results obtained after 6 months of TSH-suppressive therapy, echocardiographs recorded during acute and severe hypothyroidism (40 days after total thyroidectomy) showed abnormalities, similar to those of chronic hypothyroidism, namely, prolongation of the QT interval and flattening and inversion of the T waves (20). In acutely induced hypothyroidism, heart rate at rest was reported to be normal when compared with controls, but it was found significantly lower at rest and during exercise when compared with the same patients during TSH-suppressive therapy (21, 22).
A reduced preload was reported in patients with short-term hypothyroidism as documented by reduced left ventricular end-diastolic volume (22). Short-term hypothyroidism may worsen diastolic function as a result of altered calcium handling induced by thyroid hormone deficiency. Left ventricular mass was higher in DTC patients after 5 weeks of LT4-withdrawal than during TSH-suppression; this increase was attributed to the presence of early interstitial myxedema (23). Compared with controls, diastolic dysfunction, defined by ventricular filling, was altered in patients with short-term hypothyroidism as documented by Doppler-echocardiographs (24). The magnitude of mitral valve flow velocity curves at both the early phase (E wave) and the maximal late flow (A wave) was decreased during thyroxine withdrawal in young- and middle-aged patients with DTC (24). Additionally, isovolumic relaxation time was reported to be significantly increased during acute hypothyroidism (25), and radionuclide ventriculography with simultaneous right catheterization confirmed a lower peak filling rate (26). Thus, a reduced ejection fraction during effort was documented by radionuclide ventriculography (26).
Recent data support an increase in afterload during short-term hypothyroidism (6 weeks after LT4-withdrawal) with a consequent increased prevalence of hypertension in the same patients evaluated during LT4-suppressive therapy (27). This was recently corroborated in a study of cardiovascular function evaluated by ambulatory blood pressure monitoring, in 19 patients with DTC, in which night-time systolic, mean, and diastolic blood pressures were higher during short-term hypothyroidism versus controls and versus the same patients under TSH-suppressive treatment (21). During the hypothyroid state, adrenaline, nor-adrenaline, and cortisol were increased, probably due to their reduced clearance (28). Moreover, there would seem to be no relation between tissue sensitivity to catecholamine and thyroid status, because patients with short-term hypothyroidism had a normal response to adrenaline infusion (28).
In conclusion, adverse cardiovascular effects have been reported during acute hypothyroidism, namely, electrocardiographic abnormalities, reduced heart rate at rest and during exercise, impaired left ventricular diastolic function, impaired systolic function during effort, increased systemic vascular resistance with a reduced cardiac output, and a reduced cardiac efficiency. There is clear evidence that young- and middle-aged patients with short-term hypothyroidism may have a reduced exercise capacity and an increased prevalence of hypertension. This finding provides a plausible explanation for the worsening of hypertension, heart failure, and coronary heart disease in patients with short-term hypothyroidism and preexisting heart disease, especially in elderly patients. Therefore, rhTSH can preferably be applied for diagnostic procedures in patients who have a higher risk of adverse cardiovascular effects. Furthermore, it must also be pointed out that alterations of cardiovascular function in short-term hypothyroidism are less well tolerated because they occur in patients that are usually exposed to the effects of mild thyroid hormone excess induced by TSH-suppressive therapy (21, 29).
In another study, positron emission tomography with 11C acetate and magnetic resonance imaging was used to investigate myocardial oxidative metabolism and its relation to cardiac function and geometry in ten patients with severe acute hypothyroidism (30). In this study, cardiac oxygen consumption was lower after LT4-withdrawal (43 ± 9 days) compared with the values detected 40 ± 13 days after LT4-replacement therapy. The increase in afterload can account for the finding that the hypothyroid myocardium was energy-inefficient and the decrease in cardiac work in short-term hypothyroidism was more pronounced compared with the decrease in oxygen consumption (30).
Finally, in thyroidectomized patients with DTC taking anticoagulants, an inverse correlation between TSH and international normalized ratio after LT4-withdrawal has been recently reported, indicating that more frequent monitoring of the anticoagulation parameters and sometimes adjustment of the therapy with coumarin derivates might be required in hypothyroid patients (31).
Effects on lipids
In overt hypothyroidism, elevated levels of cholesterol and low density lipoprotein cholesterol (LDL-C) and quantitative changes that enhance its susceptibility to oxidation have been well documented (32, 33). Therefore, hypothyroidism constitutes a severe atherogenic condition. In a recent study, serum cholesteryl ester transfer protein (CETP) concentration, a crucial enzyme for the inverse cholesterol transport, was reduced in short-term hypothyroidism, but the enzyme activity was normal (34). Additionally, the size distribution of high density lipoprotein (HDL) was altered with significant lower proportions of large-sized HDL2b and HDL2a in patients before than during LT4 therapy (34). No correlations were observed between CETP and HDL or LDL in treated or untreated patients, in contrast to the negative correlation between CETP and HDL and to the positive one between CETP and LDL in normal subjects. These findings may indicate a disconnection between the changes in lipoprotein parameters and the serum CETP levels in short-term hypothyroidism. Restoration of euthyroidism by LT4 therapy usually corrects these lipid abnormalities. Though these lipid alterations are mostly reversible on restoration of euthyroidism and have no impact on recovery outcome, they should be avoided in patients with diffuse atherosclerosis and/or cardiovascular disease.
Finally, elevated levels of homocysteine (hct), a cardiovascular risk factor, were found increased in two studies with 17 and 16 patients respectively with severe hypothyroidism after withdrawal of thyroid therapy (35, 36). A strong association was detected between creatinine, cholesterol, and hct levels, suggesting that these changes are partly due to alterations in renal function (36). The elevated hct levels significantly decreased after correction of hypothyroidism.
Affective disorders and cerebral blood flow in short-term hypothyroidism
A definite link has been established between thyroid dysfunction and mood disorders, and it has been reported that patients hospitalized with hypothyroidism have a higher risk of readmission with depression than controls (37). Thyroid dysfunction-induced mood changes may be partly due to cerebral blood flow (CBF) abnormalities, as demonstrated in patients with transient hypothyroidism studied with 99mTc-HMPAO SPECT versus normal controls (38). Regional CBF alterations have been detected in the bilateral parietal lobes and in the bilateral occipital lobes, which extended to the prefrontal cortices as hypothyroidism worsened. However, these results were partly disputed in a study that correlated regional CBF and glucose metabolic activity, evaluated with the positron emission tomography 18F-labeled 2-deoxy-2-fluoro-d-glucose method, with the mental state of ten patients affected by severe hypothyroidism (TSH: 109.83 ± 40.25 mU/l) (39). That study identified a global but not regional reduction of CBF and glucose metabolic activity which may reflect a direct effect of thyroid failure on the overall brain activity. This inconsistency with other studies was explained by the authors as the result of the suddenly induced massive hypothyroidism that affects overall, not regional, brain activity. The reduction is unlikely to have been due to increased vascular resistance alone, since glucose metabolism was also impaired. This condition might be clinically reflected in the observed slowing of psychomotor function in patients rather than in their states of clinical depression (39). This mental state was interpreted as resulting from the abruptly induced deficiency of thyroid hormone, which led to the incapacity of brain cells to extract an adequate amount of oxygen and glucose from the blood.
Quality of life
Since there is no single definition of quality of life (QoL), we would suggest the definition proposed by the WHO. Thus, the term QoL is defined as an individual’s perception and expectation of a certain standard of excellence as regards his/her social and cultural environment (40). QoL accounts for every positive or negative aspect of life at physical, emotional, social, and cognitive level. Over the last few years there has been ever increasing focus on the QoL of patients with thyroid cancer and several studies have reported impaired QoL with respect to thyroid carcinoma (13, 41). In 34 subjects with DTC undergoing thyroid hormone withdrawal in preparation for scanning procedures, significant changes at both physical and psychological levels were identified with a disease-specific rating scale (13). The patients routinely reported overwhelming fatigue, anorexia, problems with motor skills, constipation, and fluid retention, all of which inevitably resulted in impaired QoL (13). They also presented diminished motivation, as well as decreased productivity and quality of work. Moreover, the study revealed that thyroid hormone withdrawal has deleterious effects, not only on the patients themselves, but also on their family and social life. In summary, the inability to perform customary household tasks and forced disengagement from participation in social activities severely disrupts the patient’s daily functioning.
A psychometric study recently evaluated QoL in 61 patients with DTC by means of a self-rating questionnaire (KSQ) and the Hamilton Depression Scale (HDS) (42). Both scales, KSQ and HSD, were significantly higher in patients than in controls, whereas HDS was significantly higher in female than in male patients.
Recently, the results were published of a 13-item survey aiming to elucidate the clinical, QoL, and pharmacoeconomic effects of hypothyroidism by comparing societal costs of withdrawal with rhTSH (43). About 92% of the patients who participated in the study had symptomatic and 85% had multisymptomatic disease, whereas half the patients needed medical support. Societal costs were calculated to be approximately 25% less for rhTSH as compared with LT4-withdrawal (43). As regards the macroeconomic scale, another study in The Netherlands has reported that roughly 59% of work hours are missed during the withdrawal period, this represents a loss of 2.5 million Euro per year to that country (44).
In another study, disturbed psychometric functionality and poor QoL in 18 women with DTC during thyroxine withdrawal as well as on long-term treatment with supraphysiological doses of LT4 were shown (45). A worsening of performance on cognitive tests, of recall of verbal information, and of physical and mental symptoms was detected in profound hypothyroidism when compared with controls.
Expanding these results, another study examined the frequency of physical complaints, health-related QoL, anxiety, and depression in 130 DTC patients hospitalized for diagnostic procedures or thyroid remnant ablation with radioiodine under short-term hypothyroidism (46). The results were compared with those of 100 DTC outpatients under suppressive doses of LT4 following radioiodine treatment.
Both groups presented impaired QoL; however, short-term hypothyroidism was accompanied by a greater decline in QoL and a higher prevalence of anxiety. Furthermore, while LT4 withdrawal significantly impairs, rhTSH use substantially reinforces compliance of patients with DTC monitoring (47).
Recently, a multicenter study was carried out to evaluate health-related QoL in 228 patients affected by DTC at three time points: on LT4, after rhTSH, and after LT4-withdrawal. Mean SF-36 Health Survey scores were compared with those of the US general population and of patients with heart failure, depression, and migraine headache. Patients’ scores declined significantly in all eight domains after LT4-withdrawal when compared with the other two time points (P > 0.001) (48). While on LT4 and after rhTSH administration, the studied subjects had SF-36 scores above those for patients with heart failure, depression, and migraine. In contrast, the scores after LT4-withdrawal were calculated significantly below the norms of heart failure, depression and migraine, once again indicating severe impairment of QoL after LT4-withdrawal that can be abrogated by rhTSH (48). Nevertheless, the strength of this study could have further been increased by the use of a specific and well-validated questionnaire (including the content validity), like the one used by Dow (13).
In summary, the results of all these studies accord in indicating severe impairment in QoL of patients with DTC when short-term hypothyroidism was induced, whereas considerable improvement is achievable when rhTSH testing is used in the management of the disease. However, one could comment that the methodology used in all the fast studies is lacking of the validity content that was provided in only one study (13). Therefore, further randomized studies comparing LT4-withdrawal and rhTSH using validated, disease-specific QoL questionnaires as outcome measures.
All relevant studies into the effects of short-term hypothyroidism on various systems are categorized according to whether they comprise a randomized controlled study, a longitudinal study, or clinical case studies (Table 1). They were rated using the modified criteria from the US Preventive Services Task Force as they have been recently published in the Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer by the American Thyroid Association Task Force (12, 49). The most studied protocols do not apply LT3 during the withdrawal period, or do not mention it. Therefore, we evaluated the number of participants, the study description, and the duration of LT4-withdrawal in the adverse effects of short-term induced hypothyroidism (Table 1).
Miscellaneous
Basal energy expenditure (BEE) and body composition were evaluated in DTC patients before diagnostic whole-body scan, during short-term hypothyroidism, and on TSH-suppressive LT4 treatment compared with healthy controls matched for age, sex, height, and weight (50). BEE, body water content, and body cell mass were significantly lower, whereas the percentage of fat was significantly higher in patients than in controls. LT4 treatment enhances BEE but the increase was not significantly different from controls. The results of this study demonstrate that even short-term deprivation of thyroid hormone has an impact on body composition and influences energy expenditure.
Thyroid hormone exerts a stimulatory effect on cell-mediated immune response represented by interleukin (IL-18) and soluble interleukin-2 receptors (sIL-2R). In a study assessing the circulating markers of cell-mediated immune response, it was shown that thyroxine withdrawal for monitoring in patients with DTC induced a reduction of IL-18, sL-2R and the percentage of natural killer cells in peripheral blood as compared with thyroxine-suppressive treatment, thus indicating that thyroid hormone modulates the cell-mediated immune response (51).
Short-term hypothyroidism after thyroid hormone withdrawal can significantly prolong both gastric half-emptying time and emptying rate, as has been reported in 22 patients with DTC (52). The disturbed gastrointestinal (GI) peristalsis results in delayed absorption of glucose from the GI-tract and reduced hepatic glucose transport, leading to a decrease in fasting glucose level.
The alternative use of rhTSH
The recent introduction of rhTSH for monitoring of thyroid cancer patients, in preparation for ablation of thyroid remnant or for metastatic disease, represents a valid alternative to the short-term hypothyroid state and a model that checks for presence of thyroid cancer (3–5). It has been established that the combination of rhTSH-stimulated Tg with neck ultrasound (providing a diagnostic sensitivity of 96.3%) offers high diagnostic accuracy in detecting persistent disease in low risk patients, while it inhibits the implications of short-term induced hypothyroidism (5, 9, 10). Its use is particularly recommended for older patients suffering from heart disease, arterial hypertension, severe arteriosclerosis, anemia, and psychic disorders where LT4-withdrawal can be life-threatening. Despite the fact that most reported observations and references represent reversible effects, short-term induced hypothyroidism should be avoided in the above-mentioned cases as well as in those patients who, due to their working and social obligations, tolerate with difficulty any impairment of their QoL.
Furthermore, its administration was not accompanied by measurable effects on heart rate, rhythm, left ventricular morphology, or systo-diastolic function (53). Additionally, an asymptomatic decrease in systolic and mean blood pressure was observed during rhTSH administration, whereas there was no effect on heart rate variability (HRV), suggesting that rhTSH does not influence the sympathovagal control of HRV when applied in patients with normal heart function (54). On this basis, rhTSH administration is clinically safe and may have beneficial effects on the vascular system by reducing arterial blood pressure and increasing circulating nitric oxide (55). Moreover, in postmenopausal, but not in premenopausal women, monitored for DTC, rhTSH administration acutely decreases the serum C-telopeptides of type-1 collagen and increases serum bone alkaline phosphatase levels, but does not affect osteoprotegerin production (56). Thus, an acute increase in serum TSH concentration leads to a marked inhibition of bone resorption.
Finally, when patients are rendered hypothyroid, there is achievement of a decreased residence time of radioiodine in the remnants and increased radiation exposure overall, as compared with the euthyroid state (57). In a study calculating the red marrow absorbed dose of high therapeutic doses of radioiodine 131I administered after rhTSH application, it was found that the bone marrow dose remained constantly below the safety level of 2 Gy (58). Therefore, the use of rhTSH may reduce the exposure of various organs to radioiodine and consequently diminish the complications rate.
Our review supports the use of rhTSH more extensively in DTC patients, since it prevents the derangement of various systems and promotes compliance, while ensuring in a safe and reliable way the quality of life in all patients.
Study description and level of evidence of several articles describing the implications of short-term hypothyroidism on various systems.
| Author | Number of patients | Duration of withdrawal | Study description | Level of evidence |
|---|---|---|---|---|
| A, strongly recommend; B, recommend. | ||||
| aTwo weeks LT3. | ||||
| Cardiovascular effects | ||||
| Grossman et al. (24) | 11 | 6 Weeks | Case-controlled study | A |
| Bengel et al. (30) | 10 | 5 Weeks | Longitudinal study | B |
| Constant et al. (39) | 10 | 5 Weeks | Longitudinal study | B |
| Fomei et al. (27) | 12 | 6 Weeks | Longitudinal study | B |
| Botella-Carretero et al. (18) | 21 | 5 Weeks | Case-controlled study | A |
| Giusti et al. (36) | 61 | Variable | Case-controlled study | A |
| Neurocognition and well-being | ||||
| Nagamachi et al. (38) | 24 | 4 Weeks | Case-controlled study | A |
| Quality of life | ||||
| Dow et al. (13) | 34 | – | Longitudinal repeated-measures | A |
| Botella-Carretero et al. (45) | 18 | 5 Weeks | Case-controlled study | B |
| Tagay et al. (46) | 130 | 4 Weeks | Case-controlled study | B |
| Luster (43) | 130 | 4 Weeks | Retrospective/questionnaire | B |
| Schroeder PR et al. (48) | 228 | 4 Weeksa | Longitudinal/SF-36 HS | A |
References
- 1↑
Davies L & Welch HG. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 2006 295 2179–2182.
- 2↑
Singer PA, Cooper DS, Daniels GH, Ladenson PW, Greenspan FS, Levy EG, Braverman LE, Clark OH, McDougall IR, Ain KV & Dorfman SG. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid carcinoma. American Thyroid Association. Archives of Internal Medicine 1996 156 2165–2172.
- 3↑
Sclumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Pacini F, Reiners C, Franco FS, Toft A & Wiersinga WM. Follow up of low risk patients with differentiated thyroid carcinoma: a European perspective. European Journal of Endocrinology 2004 150 105–112.
- 4
Ringel MD & Ladenson PW. Controversies in the follow up and management of well differentiated thyroid carcinoma. Endocrine Related Cancer 2004 11 97–116.
- 5↑
Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Reiners C, Sanchez Franco F, Smit J & Wiersinga W. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. European Journal of Endocrinology 2005 153 651–659.
- 6↑
Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW & Pinchera A. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2003 88 1433–1441.
- 7↑
Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garger JR, Wondisford EE, Davies TF, De Groot LJ, Daniels GH, Ross DS & Weintraub BD. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. New England Journal of Medicine 1997 337 888–896.
- 8
Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD & Ridgway EC. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. Journal of Clinical Endocrinology and Metabolism 1999 84 3877–3885.
- 9↑
Kohlfuerst S, Igerc I & Lind P. Recombinant human thyrotropin is helpful in the follow-up and 131I therapy of patients with thyroid cancer: a report of the results and benefits using recombinant human thyrotropin in clinical routine. Thyroid 2005 15 371–376.
- 10↑
Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M & Reiner C. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. Journal of Clinical Endocrinology and Metabolism 2005 91 926–932.
- 11↑
Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW & Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology 2006 154 787–803.
- 12↑
The American Thyroid Association Guidelines Taskforce. Management guidelines for patient with thyroid nodules and differentiated thyroid cancer. Thyroid 2006 16 109–141.
- 13↑
Dow KH, Ferrell BR & Anello C. Quality of life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997 7 613–619.
- 14↑
Biondi B & Klein I. Hypothyroidism as a risk factor for cardiovascular disease. Endocrine 2004 24 1–13.
- 15
Duntas LH. Thyroid disease and lipids. Thyroid 2002 12 287–293.
- 16↑
Cappola AR & Ladenson PW. Hypothyroidism and atherosclerosis. Journal of Clinical Endocrinology and Metabolism 2003 88 2438–2444.
- 17↑
Klein I & Ojamaa K. Thyroid hormone and the cardiovascular system. New England Journal of Medicine 2001 344 501–509.
- 18↑
Biondi B & Klein I. Cardiovascular abnormalities in subclinical and overt hypothyroidism. In The Thyroid and Cardiovascular Risk, pp 30–35. Eds KM Derwahl, LH Duntas & S Butz, Thieme Verlag: Stuttgart, 2005.
- 19↑
Biondi B, Palmieri EA, Lombardi G & Fazio S. Effects of subclinical thyroid dysfunction on the heart. Annals of Internal Medicine 2002 137 904–914.
- 20↑
Fazio S, Biondi B, Lupoli G, Cittadini A, Santomauro M, Tommaselli AP, Lombardi G & Saccà L. Evaluation by noninvasive methods of the effects of acute loss of thyroid hormone on the heart. Angiology 1992 43 287–293.
- 21↑
Botella-Carretero JL, Gómez-Bueno M, Barrios V, Caballero C, García-Robles R, Sancho J & Escobar-Morreale HF. Chronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are associated with undesirable cardiovascular effects in patients with differentiated thyroid carcinoma. Endocrine Related Cancer 2004 11 345–356.
- 22↑
Di Paola R, Alagona C, Pezzino V, Mangiameli S & Regalbuto C. Left ventricular function in acute hypothyroidism: a Doppler echocardiography study. Italian Heart Journal 2004 5 857–863.
- 23↑
Wieshammer S, Keck FS, Waitzinger J, Kohler J, Adam W, Stauch M & Pfeiffer EF. Left ventricular function at rest and during exercise in acute hypothyroidism. British Heart Journal 1988 60 204–211.
- 24↑
Grossman G, Wieshammer S, Keck FS, Goeller V, Glesler M & Hombach V. Doppler echocardiographic evaluation of left ventricular diastolic function in acute hypothyroidism. Clinical Endocrinology 1994 40 227–233.
- 25↑
Kahaly G, Mohr-Kahaly S, Beyer J & Meyer J. Left ventricular function analyzed by Doppler and echocardiographic methods in short-term hypothyroidism. American Journal of Cardiology 1995 75 645–648.
- 26↑
Wieshammer S, Keck FS, Waitzinger J, Henze E, Loos U, Hombach V & Pfeiffer EF. Acute hypothyroidism slows the rate of left ventricular diastolic relaxation. Canadian Journal of Physiology and Pharmacology 1989 67 1007–1010.
- 27↑
Fommei E & Iervasi G. The role of thyroid hormone in blood pressure homeostasis: evidence from short-term hypothyroidism in humans. Journal of Clinical Endocrinology and Metabolism 2002 87 1996–2000.
- 28↑
Johnson AB, Webber J, Mansell P, Gallen I, Allison SP & Macdonald I. Cardiovascular and metabolic responses to adrenaline infusion in patients with short-term hypothyroidism. Clinical Endocrinology 1995 43 747–751.
- 29↑
Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S & Lombardi G. Subclinical hyperthyroidism: clinical features and treatment options. European Journal of Endocrinology 2005 152 1–9.
- 30↑
Bengel FM, Nekolla SG, Ibrahim R, Weniger C, Ziegler SI & Schwaiger M. Effect of thyroid hormones on cardiac function, geometry and oxidative metabolism assessed noninvasively by positron emission tomograpy and magnetic resonance imaging. Journal of Clinical Endocrinology and Metabolism 2000 85 1822–1827.
- 31↑
Bucerius J, Joe AY, Palmedo H, Reinhardt MJ & Biersack HJ. Impact of short-term hypothyroidism on systemic anticoagulation in patients with thyroid cancer and coumarin therapy. Thyroid 2006 16 369–374.
- 32↑
Staub JJ, Althaus BU, Engler H, Ryff AS, Trabucco P, Marquardt K, Burckhardt D, Girard J & Weintraub BD. Spectrum of subclinical and overt hypothyroidism: effect on thyrotropin, prolactin, and thyroid reserve and metabolic impact on peripheral target tissues. American Journal of Medicine 1992 92 631–642.
- 33↑
Duntas LH, Mantzou E & Koutras DA. Circulating levels of oxidized low-density lipoprotein in overt and mild hypothyroidism. Thyroid 2002 12 1003–1007.
- 34↑
Dedecjus M, Masson D, Gautier T, de Barros JP, Gambert P, Lewinski A, Adamczewski Z, Moulin P & Lagrost L. Low cholesteryl ester transfer protein (CETP) concentration but normal CETP activity in serum from patients with short term hypothyroidism lack of relationship to lipoprotein abnormalities. Clinical Endocrinology 2003 58 581–588.
- 35↑
Lien EA, Nedrebo BG, Varhaug JE, Nygard O, Aakvaag A & Ueland PM. Plasma total homocysteine levels during short-term iatrogenic hypothyroidism. Journal of Clinical Endocrinology and Metabolism 2000 85 1049–1053.
- 36↑
Bicikova M, Hampl R, Hill M, Stanicka S, Tallova J & Vondra K. Steroids, sex hormone-binding globulin, homocysteine, selected hormones and markers of lipid and carbohydrate metabolism in patients with severe hypothyroidism and their changes following thyroid hormone supplementation. Clinical Chemistry and Laboratory Medicine 2003 41 284–292.
- 37↑
Thomsen AF, Kvist TK, Andersen PK & Kessing LV. Increased risk of developing affective disorder in patients with hypothyroidism: a register–based study. Thyroid 2005 15 700–707.
- 38↑
Nagamachi S, Jinnouchi S, Nishii R, Ishida Y, Fujita S, Futami S, Kodama T, Tamura S & Kawai K. Cerebral blood flow abnormalities induced by transient hypothyroidism after thyroidectomy – analysis by tc-99m-HMPAO and SPM96. Annals of Nuclear Medicine 2004 18 469–477.
- 39↑
Constant EL, De Volder AG, Ivanoiu A, Bol A, Labar D, Seghers A, Cosnard G, Melin J & Daumerie C. Cerebral blood flow and glucose metabolism in hypothyroidism: a positron emission tomography study. Journal of Clinical Endocrinology and Metabolism 2001 86 3864–3870.
- 40↑
WHOQOL Group. Study protocol for the World Health Organisation project to develop a quality of life assessment instrument (the WHOQOL). Quality of Life Research 1993 2 153–159.
- 41↑
Kaplan M. Progress in thyroid cancer. Endocrinology and Metabolism Clinics of North America 1990 19 469–478.
- 42↑
Giusti M, Sibilla F, Cappi C, Dellepiane M, Tombesi F, Ceresola E, Augeri C, Rasore E & Minuto F. A case-controlled study on the quality of life in a cohort of patients with history of differentiated thyroid carcinoma. Journal of Endocrinological Investigation 2005 28 599–608.
- 43↑
Luster M, Felbinger R, Dietlein M & Reiners C. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid 2005 15 1147–1155.
- 44↑
Nijhuis TF, van Weperen W & de Klerk JMH. Costs associated with the withdrawal of thyroid hormone suppression therapy during the follow-up treatment of well-differentiated thyroid cancer. Tijdschr Nucl Geneeskd 1999 21 98–100.
- 45↑
Botella-Carretero JI, Galán JM, Caballero C, Sancho J & Escobar-Morreale HF. Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma. Endocrine Related Cancer 2003 10 601–610.
- 46↑
Tagay S, Herpertz S, Langkafel M, Erim Y, Freudenberg L, Schöpper N, Bockisch A, Sent W & Görges R. Health-related quality of life, anxiety and depression in thyroid cancer patient under short-term hypothyroidism and TSH suppressive levothyroxine treatment. European Journal of Endocrinology 2005 6 755–763.
- 47↑
Cohen O, Dabhi S, Karasik A & Zwas SZ. Compliance with follow-up and the informative value of diagnostic whole-body scan in patients with differentiated thyroid carcinoma given recombinant human TSH. European Journal of Endocrinology 2004 150 285–290.
- 48↑
Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC & Ladenson PW. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. Journal of Clinical Endocrinology and Metabolism 2006 91 878–884.
- 49↑
US Preventive Services Task Force Ratings Strength of Recommendations and Quality of Evidence 2000–2003. Guide to Clinical Preventive Services, edn 3, Periodic Updates. Agency for Healthcare Research and Quality, Rockville, MD.
- 50↑
Wolf M, Weigert A & Kreymann G. Body composition and energy expenditure in thyroidectomized patients during short-term hypothyroidism and thyrotropin-suppressive thyroxine therapy. European Journal of Endocrinology 1996 134 168–173.
- 51↑
Botella-Carretero JI, Prados A, Manzano L, Montero MT, Escribano L, Sancho J & Escobar-Morreale HF. The effects of thyroid hormones on circulating markers of cell-mediated immune response, as studied in patients with differentiated thyroid carcinoma before and during thyroxine withdrawal. European Journal of Endocrinology 2005 153 223–230.
- 52↑
Kao PF, Lin JD, Chiu CT, Hsu HT, See LC & Tzen KY. Gastric emptying function changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Journal of Gastroenterology and Hepatology 2004 19 655–660.
- 53↑
Biondi B, Palmieri EA, Pagano L, Klain M, Scherillo G, Salvatore M, Fenzi G, Lombardi G & Fazio S. Cardiovascular safety of acute recombinant human thyrotropin administration to patients monitored for differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2003 88 211–214.
- 54↑
Murialdo G, Casu M, Cappi C, Patrone V, Repetto E, Copello F, Minuto F & Giusti M. Effects of recombinant human thyrotropin on heart rate variability and blood pressure in patients on l-thyroxine-suppressive therapy for differentiated thyroid carcinoma. Hormone Research 2005 64 100–106.
- 55↑
Giusti M, Valenti S, Guazzini B, Molinari E, Cavallero D, Augeri C & Minuto F. Circulating nitric oxide is modulated by recombinant human TSH administration during monitoring of thyroid cancer remnant. Journal of Endocrinological Investigation 2003 26 1192–1197.
- 56↑
Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, Biondi B, Iorio S, Giustina A, Amato G & Carella C. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. Journal of Bone and Mineral Research 2005 20 480–486.
- 57↑
Luster M, Sherman SL, Skarulis MC, Reynolds JR, Lassmann M, Hanscheid H & Reiners C. Comparison of radionuclide biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging 2003 30 1371–1377.
- 58↑
de Keizer B, Hoekstra A, Konijnenberg MW, de Vos F, Lambert B, van Rijk PP, Lips CJ & de Klerk JM. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer. Journal of Nuclear Medicine 2004 45 1549–1554.
